Eli Lilly Is Buying AtaiBeckley for Up to $3.8 Billion — Big Pharma's First Psychedelic Buyout
Eli Lilly announced on July 16, 2026 that it will acquire AtaiBeckley — the company formed just months earlier when ATAI Life Sciences merged with Beckley Psytech — for $6.75 per share in cash upfront (about $2.8 billion) plus up to $2.50 per share more through a contingent value right tied to future milestones, putting the deal's total potential value at $3.8 billion. The acquisition is expected to close this quarter and is the first time a major pharmaceutical company has bought a psychedelic drug developer outright, rather than licensing or partnering. The deal centers on AtaiBeckley's 5-MeO-DMT candidate mebufotenin (BPL-003), which posted positive Phase 2b results for treatment-resistant depression earlier this year. It's a genuinely new kind of signal for the sector: after years of biotechs partnering with or licensing individual compounds to Big Pharma, this is the first full buyout — the closest thing yet to an answer on whether Big Pharma sees this as a real, ownable business or just a research bet worth watching from a distance.
Read at CNBC